Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For CLVS
-
Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?
-
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
-
Clovis: Q3 Earnings Snapshot
-
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know
-
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
-
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
-
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
-
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
-
Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?
-
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
-
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
-
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
-
Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?
-
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
-
Why Is Clovis (CLVS) Down 32% Since Last Earnings Report?
-
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
-
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
-
Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?
-
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
-
Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates
-
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
-
Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound?
-
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales
-
Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates